|
Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >
Improved Long-Term Survival with Edaravone Therapy in Patients with Amyotrophic Lateral Sclerosis : A Retrospective Single-Center Study in Japan
| Title: | Improved Long-Term Survival with Edaravone Therapy in Patients with Amyotrophic Lateral Sclerosis : A Retrospective Single-Center Study in Japan |
| Authors: | Houzen, Hideki Browse this author | | Kano, Takahiro Browse this author | | Horiuchi, Kazuhiro Browse this author | | Wakita, Masahiro Browse this author | | Nagai, Azusa Browse this author | | Yabe, Ichiro Browse this author →KAKEN DB |
| Keywords: | amyotrophic lateral sclerosis | | edaravone | | survival rate |
| Issue Date: | Aug-2021 |
| Publisher: | MDPI |
| Journal Title: | Pharmaceuticals |
| Volume: | 14 |
| Issue: | 8 |
| Start Page: | 705 |
| Publisher DOI: | 10.3390/ph14080705 |
| Abstract: | Reports on the long-term survival effect of edaravone, which was approved for the treatment of amyotrophic lateral sclerosis (ALS) in 2015 in Japan, are rare. Herein, we report our retrospective analysis of 45 consecutive patients with ALS who initially visited our hospital between 2013 and 2018. Of these, 22 patients were treated with edaravone for an average duration of 26.6 (range, 2-64) months, whereas the remaining patients were not treated with edaravone and comprised the control group. There were no differences in baseline demographics between the two groups. The primary endpoint was tracheostomy positive-pressure ventilation (TPPV) or death, and the follow-up period ended in December 2020. The survival rate was significantly better in the edaravone group than in the control group based on the Kaplan-Meier analysis, which revealed that the median survival durations were 49 (9-88) and 25 (8-41) months in the edaravone and control groups, respectively (p = 0.001, log-rank test). There were no serious edaravone-associated adverse effects during the study period. Overall, the findings of this single-center retrospective study suggest that edaravone might prolong survival in patients with ALS. |
| Type: | article |
| URI: | http://hdl.handle.net/2115/83242 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
|
